דורבלומאב (Hebrew Wikipedia)

Analysis of information sources in references of the Wikipedia article "דורבלומאב" in Hebrew language version.

refsWebsite

Global rank Hebrew rank

2^nd place

10^th place

447^th place

285^th place

1web.archive.org

1^st place

6^th place

1frontiersin.org

4,679^th place

677^th place

234^th place

92^nd place

1sciencedirect.com

149^th place

87^th place

low place

low place

719^th place

349^th place

low place

766^th place

cancer.org.il

דורבלומאב - Durvalumab (אימפינזי®-Imfinzi®)*, באתר האגודה למלחמה בסרטן

doi.org

dx.doi.org

Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K. Kashaw, Arun K. Iyer, PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome, Frontiers in Pharmacology 8, 2017 doi: 10.3389/fphar.2017.00561/full
Arlene H. Sharpe, Kristen E. Pauken, The diverse functions of the PD1 inhibitory pathway, Nature Reviews Immunology 18, 2018-03, עמ' 153–167 doi: 10.1038/nri.2017.108
Clemence Granier, Eleonore De Guillebon, Charlotte Blanc, Helene Roussel, Cecile Badoual, Elia Colin, Antonin Saldmann, Alain Gey, Stephane Oudard, Eric Tartour, Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer, ESMO Open 2, 2017-01-01, עמ' e000213 doi: 10.1136/esmoopen-2017-000213
Akintunde Akinleye, Zoaib Rasool, Immune checkpoint inhibitors of PD-L1 as cancer therapeutics, Journal of Hematology & Oncology 12, 2019-09-05, עמ' 92 doi: 10.1186/s13045-019-0779-5

doi.org

Akintunde Akinleye, Zoaib Rasool, Immune checkpoint inhibitors of PD-L1 as cancer therapeutics, Journal of Hematology & Oncology 12, 2019-09-05, עמ' 92 doi: 10.1186/s13045-019-0779-5

drugbank.com

go.drugbank.com

Durvalumab, go.drugbank.com

fda.gov

Research, Center for Drug Evaluation and. "Approved Drugs - Durvalumab (Imfinzi)". www.fda.gov. ארכיון מ-8 במאי 2017. נבדק ב-2017-05-06. {{cite web}}: (עזרה)

frontiersin.org

Hashem O. Alsaab, Samaresh Sau, Rami Alzhrani, Katyayani Tatiparti, Ketki Bhise, Sushil K. Kashaw, Arun K. Iyer, PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome, Frontiers in Pharmacology 8, 2017 doi: 10.3389/fphar.2017.00561/full

medscape.com

reference.medscape.com

Imfinzi (durvalumab) dosing, indications, interactions, adverse effects, and more, reference.medscape.com

nature.com

Arlene H. Sharpe, Kristen E. Pauken, The diverse functions of the PD1 inhibitory pathway, Nature Reviews Immunology 18, 2018-03, עמ' 153–167 doi: 10.1038/nri.2017.108

sciencedirect.com

Clemence Granier, Eleonore De Guillebon, Charlotte Blanc, Helene Roussel, Cecile Badoual, Elia Colin, Antonin Saldmann, Alain Gey, Stephane Oudard, Eric Tartour, Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer, ESMO Open 2, 2017-01-01, עמ' e000213 doi: 10.1136/esmoopen-2017-000213

web.archive.org

Research, Center for Drug Evaluation and. "Approved Drugs - Durvalumab (Imfinzi)". www.fda.gov. ארכיון מ-8 במאי 2017. נבדק ב-2017-05-06. {{cite web}}: (עזרה)